

From: Walls, Chuck G SC-CHSE-CW
Sent: Thursday, August 16, 2001 7:55 AM
To: Clegg, Patsy M SCC-CHSE-PC; Smith, James JM SC-CSP
Cc: Draper, Joe J SC-CHSE-JFD; Owen, David DE SC-CHSE-DO; Cagen, Stuart Z SCC; Tsai, Shan SP SHLOIL-SPS; Sullivan, Nancy E SCC-CBAR
Subject: RE: China Study and Animal Testing
Patsy,

Epidemiology studies are quite acceptable. Controlled dose-response experimental studies on human beings would require intensive review and approval at a very senior management level as well as approval of an Ethics Panel. Based on what you have described, this is merely an epidemiology study.

Chuck Walls
Vice-President: HSE
Shell Chemicals Limited
Shell Centre, London SE1 7NA, United Kingdom

Tel: +44 (0)20 7934 5761 **Fax:** 7155 **Other Tel:** mobile +44 (0)777 165 0296
Email: Chuck.G.Walls@opc.shell.com
Internet: <http://www.shell.com>

-----Original Message-----

From: Clegg, Patsy M SCC-CHSE-PC
Sent: 16 August 2001 13:45
To: Smith, James JM SC-CSP; Walls, Chuck G SC-CHSE-CW
Cc: Draper, Joe J SC-CHSE-JFD; Owen, David DE SC-CHSE-DO; Cagen, Stuart Z SCC; Tsai, Shan SP SHLOIL-SPS; Sullivan, Nancy E SCC-CBAR
Subject: China Study and Animal Testing

The CEC has endorsed and Shell has sent a letter of commitment to participate with 4 other companies (ExxonMobil, Chevron, BP, and Conoco) in a large study of a benzene-exposed population in Shanghai, China. The study will cost approximately \$20M (Shell's commitment is a max of \$3M) and take just over 5 years. The "benzene-exposed population" will be identified by local Shanghai hospitals where workers are diagnosed with benzene poisoning, AML, or other illnesses and there is known potential occupational benzene exposure. Exposure data will be provided by the Shanghai province equivalent of the US Center for Disease Control. Blood samples from this population will be used in support of a prospective epidemiology study, a disease progression and biological markers study. The protocols and consent forms have been reviewed and approved by an Ethics Panel using the UN Epidemiology Guidelines.

The timeline for the project has contracts being signed and checks being written by the end of August. So, the question is: Can Shell continue to participate? Are humans participating in an epidemiology study, similar to our existing medical monitoring programs, included in the animal testing policy?

I would be happy to provide any additional details if requested.

Patsy

Patsy M. Clegg
Product Steward, HSE
Shell Chemical Company, PO Box 4320, Houston, TX 77002
Phone: 713-241-2521 FAX: 713-241-3325
e-mail: pmclegg@shellus.com

SHELL-MCCLURG-067966

